News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Myers Industries (NYSE: MYE) reported strong Q2 2026 results
Myers Industries has refinanced its credit facilities, adding a new $250 million Term Loan Facility and extending maturities to 2031, while also reporting strong financial results for Q2 2026. The company achieved a 9.8% increase in net sales, a 57.1% rise in operating income, …
Myers Industries (MYE) reported strong financial results for Q2 2026, with net sales increasing by 9.8% to $179.2 million and diluted EPS reaching $0.50. The company saw significant growth in its Infrastructure and Food & Beverage end markets, while Vehicle and Consumer segments experienced …
Bristol Myers Squibb raised its full-year earnings and revenue outlook after reporting increased profit and revenue in the latest quarter. The biopharmaceutical company now forecasts earnings of $6.75 to $7 per share and revenue of $49 billion to $50 billion, an increase from its …
Bristol Myers Squibb significantly raised its full-year revenue and profit forecasts for 2026 after reporting strong second-quarter results, driven by robust sales of blood thinner Eliquis and newer drugs like Camzyos and Reblozyl. The company's strategy to counter sales declines from older medicines facing …
Bristol-Myers Squibb (NYSE:BMY) reported strong Q2 CY2026 financial results, surpassing analyst expectations for both revenue and non-GAAP profit. The company's revenue grew 5.7% year-on-year to $12.97 billion, and its full-year revenue guidance of $49.5 billion also exceeded estimates. Despite strong quarterly performance, the company …
Edgestream Partners L.P. has acquired a new position in Bristol Myers Squibb Company (NYSE:BMY), purchasing 154,427 shares valued at approximately $9.366 million during the first quarter. This increased institutional ownership in the biopharmaceutical company, with other major investors like Vanguard Group Inc., State Street …
The Manufacturers Life Insurance Company increased its holdings in Bristol Myers Squibb (NYSE:BMY) by 15.8% in the first quarter, adding 241,405 shares to reach a total value of approximately $107.1 million. Institutional investors now own 76.41% of BMY, while analyst sentiment remains mixed with …
Opal Capital LLC recently acquired 22,664 shares of Bristol Myers Squibb (NYSE:BMY) in the first quarter, valued at approximately $1,375,000. Other institutional investors have also adjusted their holdings in the biopharmaceutical company, which has seen its stock perform within a 12-month range of $42.52 …
Myers Industries Inc (MYE) currently has a valuation score of 7.29, ranking 16th out of 21 in the Containers & Packaging industry. Its P/E ratio stands at 47.58, which is 42.21% below its recent high and 75.13% above its recent low. The company has …
This article provides a comprehensive overview of Bristol-Myers Squibb Co (BMY) stock, including real-time quotes, key financial figures, performance trends, and analyst ratings. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The stock is currently rated …
The California State Teachers Retirement System reduced its stake in Bristol Myers Squibb Company (BMY) by 2.3% in the first quarter, now owning 3,317,201 shares valued at $201.19 million. Other institutional investors have also adjusted their positions in the biopharmaceutical company. Analysts currently rate …
Empowered Funds LLC significantly reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 38.0% during the first quarter, selling 210,880 shares and leaving them with 344,513 shares valued at over $20 million. Other institutional investors like Swiss RE Ltd., Darwin Wealth Management LLC, …
Bristol Myers Squibb (BMS) is set to become the first life sciences company to acquire NVIDIA's latest generation supercomputer, the NVIDIA DGX SuperPOD with AIDGX Vera Rubin NVL72 systems. This move deepens a three-year partnership between the two companies, aiming to accelerate drug discovery …
Bristol Myers Squibb (BMY) has seen a 42.2% return over the past year, with a Discounted Cash Flow (DCF) model suggesting its intrinsic value is significantly higher than its current share price, implying it's undervalued by 48.1%. The company's expansion into AI-driven drug discovery …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol-Myers Squibb (BMY) is set to report its Q2 earnings this Thursday before market open. The company previously beat revenue expectations but slightly missed full-year EPS guidance. Analysts generally anticipate a 6.3% year-over-year revenue decline this quarter, while investor sentiment for the pharmaceutical sector …
Myers Industries Inc is projected to report earnings of 36 cents per share. This information comes from a Reuters article, highlighting an upcoming earnings preview for the company.
New approvals for Biokin’s Iza-bren, a first-in-class EGFRxHER3 bispecific ADC, for advanced nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma, highlight China's growing influence in this field. Biokin aims for global commercialization, leveraging its first-mover advantage and partnership with Bristol Myers Squibb. …
Lazard Asset Management LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 23.7% in the first quarter, now owning 1,924,036 shares valued at $116.69 million. Other institutional investors like Vanguard Group Inc., State Street Corp, and Geode Capital Management LLC also significantly …
Raymond James reiterated a Market Perform rating on Bristol-Myers Squibb (NYSE:BMY), stating that recent ZEPHYR trial data for ML-007C-MA does not pose a risk to Cobenfy and confirms its strong position in schizophrenia treatment. The firm believes Cobenfy has a significant commercial and clinical …
Sharemaestro market context Trend signal active 52 weeks +19.5%Bristol Myers Squibb (NYSE:BMY) recently hit a new 52-week high of $63.24, trading around $63.07, and has a market capitalization of approximately $128.1 billion. Analyst sentiment is mixed, with 8 buys, 10 holds, and 1 sell rating, and an average price target of $61.25, …
Bristol Myers Squibb (BMS) has launched Relopduo, a fixed-dose combination for unresectable or metastatic melanoma, in India. This drug, which combines nivolumab and relatlimab, is the first FDA-approved FDC of two immune checkpoint inhibitors. Priced at ₹2,99,900 per vial, it offers a new treatment …
Theo Ai has appointed Sandra Leung, former Executive Vice President and General Counsel of Bristol Myers Squibb, to its Board of Directors, enhancing the company's governance and strategic direction. Leung's extensive experience in litigation, corporate governance, and risk management will help tailor Theo Ai's …
Theo Ai has appointed Sandra Leung, former EVP and General Counsel of Bristol Myers Squibb, to its board of directors. Leung previously served on Theo Ai’s General Counsel Advisory Board and brings over 30 years of corporate legal experience, including expertise in litigation risk …
BMO Capital has reiterated its Market Perform rating and $60.00 price target for Bristol-Myers Squibb (NYSE: BMY), citing the competitive advantage of its schizophrenia drug, Cobenfy. This follows a failed Phase 2 trial for a competing drug, ML-007C-MA, which did not meet statistical significance. …
Bristol-Myers Squibb (BMY) stock recently hit a new 52-week high of $62.89, trading at $62.95 with a market capitalization of $127.94 billion. The company has maintained dividend payments for 56 consecutive years, currently yielding 4.06%. This milestone follows the FDA's acceptance of their New …
Myers Industries, Inc. (MJF) generated €703.05 million in revenue last year. The Material Handling segment was the top performer, contributing €529.71 million, and the United States was the primary regional contributor with €654.95 million. The report provides a breakdown of the company's revenue by …
Search by ticker symbol or company name and select a result to open its chart.